SparingVision announces Oral Presentation of SPVN06 Data at ASGCT 2022
Paris, May 3, 2022 – SparingVision (“the Company”), a genomic medicine company developing vision saving treatments for ocular diseases, a genomic medicine company developing vision saving treatments for ocular diseases, announces today that it has been selected for an oral presentation at the ASGCT 25th Annual Meeting, taking place May 16-19, 2022 in Washington D.C.
Dr. Florence Lorget, Chief Development Sciences Officer at SparingVision, will present pharmacology and safety data on its lead product SPVN06, a gene and mutation-independent gene therapy developed in Retinitis Pigmentosa.
More information below:
Oral Presentation: SPVN06, a Novel Mutation-Independent AAV-Based Gene Therapy, Dramatically Reduces Vision Loss in the rd10 Mouse Model of Rod-Cone Dystrophy and is Well Tolerated in a 1-Month Pilot Safety Monkey Study
Date and Time: 19 May, 10:45AM- 11:AM EDT, Salon G
Presenter: Dr. Florence Lorget
Session Title: Ophthalmic and Auditory Diseases
**ENDS**